Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

被引：0
|
作者：
Katalinic, D. [1 ]
机构：
[1] JJ Strossmayer Univ Osijek, Fac Med, Dept Internal Med, Zagreb, Croatia
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
772
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [1] Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
    Marin, David
    Ibrahim, Amr R.
    Lucas, Claire
    Gerrard, Gareth
    Wang, Lihui
    Szydlo, Richard M.
    Clark, Richard E.
    Apperley, Jane F.
    Milojkovic, Dragana
    Bua, Marco
    Pavlu, Jiri
    Paliompeis, Christos
    Reid, Alistair
    Rezvani, Katayoun
    Goldman, John M.
    Foroni, Letizia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 232 - 238
  • [2] Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib
    Milojkovic, Dragana
    Ibrahim, Amr R.
    Foroni, Letizia
    Lucas, Claire
    Gerrard, Gareth
    Wang, Lihui
    Szydlo, Richard M.
    Clark, Richard E.
    Apperley, Jane F.
    Bua, Marco
    Pavlu, Jiri
    Paliompeis, Christos
    Reid, Alistair
    Rezvani, Katy
    Goldman, John M.
    Marin, David
    BLOOD, 2011, 118 (21) : 729 - 729
  • [3] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [4] CLINICAL SIGNIFICANCE OF COMBINING BCR-ABL1 TRANSCRIPT LEVELS AT 3 AND 6 MONTHS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FRONTLINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S. E.
    Choi, S. Y.
    Kim, S. H.
    Oh, Y. J.
    Chae, M. J.
    Song, H. Y.
    Yoo, H. L.
    Lee, M. Y.
    Jang, E. J.
    Jeong, K. H.
    Lee, J. S.
    Kim, D. W.
    HAEMATOLOGICA, 2014, 99 : 599 - 599
  • [5] Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Malik, Sara
    Hassan, Shahzeb
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 975 - 978
  • [6] Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis
    Chen, Kangkang
    Ruan, Yingying
    Tian, Kewei
    Xiong, Peisheng
    Xia, Nan
    Li, Jin
    Huang, Wen
    Cao, Feiyan
    Chen, Qifeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Issa, Ghayas C.
    Jabbour, Elias
    Sasaki, Koji
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1714 - 1717
  • [8] The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia
    Ercaliskan, Abdulkadir
    Eskazan, A. Emre
    CANCER, 2018, 124 (19) : 3806 - 3818
  • [9] EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Noh, H.
    Choi, S. -Y.
    Song, H. -Y.
    Kim, S. -H.
    Jung, S. Y.
    Yang, S.
    Lee, W. -S.
    Kim, H. -J.
    Kong, J. H.
    Kim, H.
    Do, Y. R.
    Kwak, J. -Y.
    Oh, S.
    Kim, S. H.
    Kim, J. -A.
    Zang, D. Y.
    Mun, Y. -C.
    Won, Y. -W.
    Lee, S. -E.
    Kim, D. -W.
    Lee, J.
    HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [10] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
    Kihel, I.
    Nachi, M.
    Cayuela, J.
    Bekadja, M. A.
    Note, A.
    CLINICA CHIMICA ACTA, 2024, 558
12345